Lidocaine

CAS 137-58-6 13 current records 7 historical

Who holds supplier records for Lidocaine? 13 organisations hold a current record for Lidocaine: an active US FDA Type II Drug Master File or a CEP. A further 7 organisations have only historical (inactive) DMF filings. 8 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (5), China (3), Sweden (1), Taiwan (1) and 3 other countries (3).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Lidocaine: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/lidocaine

Reading the evidence

  • 13 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 3 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Lidocaine expires 10 May 2031. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (13)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Lidocaine. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Lidocaine sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (8)

Certificates of Suitability on the EDQM register for Lidocaine, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
APEX HEALTHCARE LIMITED AnkleshwarIN
CEP 2024-291 - Rev 00
Lidocaine
Jan 2026—
SHANDONG CHENGHUI SHUANGDA PHARMACEUTICAL CO., LTD. Dezhou CityCN
CEP 2024-285 - Rev 00
Lidocaine
Oct 2025—
HARMAN FINOCHEM LIMITED MumbaiIN
CEP 2014-234 - Rev 02
Lidocaine
Apr 2025—
SWATI SPENTOSE PRIVATE LIMITED MumbaiIN
CEP 2013-138 - Rev 03
Lidocaine
Mar 2025—
Moehs Iberica S.L. RubiES
CEP 1998-078 - Rev 06
Lidocaine
Sept 2024—
SOCIETÀ ITALIANA MEDICINALI SCANDICCI S.I.M.S. S.R.L ReggelloIT
CEP 2004-156 - Rev 02
Lidocaine
Feb 2024Inspected Nov 2024
Italy
DELTA SYNTHETIC CO., LTD. New Taipei CityTW
R1-CEP 2010-320 - Rev 01
Lidocaine
Jul 2020—
CAMBREX KARLSKOGA AB KarlskogaSE
R1-CEP 2011-326 - Rev 00
Lidocaine
May 2018—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (7)

Organisations whose Type II DMFs for Lidocaine are no longer active. These show a past filing, not current supply.

Show all 7 historical records
  • GUFIC BIOSCIENCES LTD
    Inactive DMF 20789 · filed Aug 2007
  • Taiwan · Inactive DMF 18005 · filed Jan 2005
  • HOECHST AG
    Inactive DMF 5921 · filed Jul 1985
  • PROFARMACO SRL
    Inactive DMF 4140 · filed Mar 1981
  • WARD BLENKINSOP AND CO LTD
    Inactive DMF 3137 · filed Jan 1978
  • NAPP CHEMICALS INC
    Inactive DMF 2708 · filed Jul 1976
  • JENSEN-SALSBERY LABS DIV RICHARDSON-MERRILL INC
    Inactive DMF 250 · filed Jan 1940

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (102 listed products contain Lidocaine). The latest listed patent expires 10 May 2031. The latest listed exclusivity runs to 24 Sept 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Lidocaine is an active pharmaceutical ingredient with CAS number 137-58-6.

Chemical identity

IUPAC name
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
Canonical SMILES
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C
InChIKey
NNJVILVZKWQKPM-UHFFFAOYSA-N

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Amide Local Anesthetic; Antiarrhythmic
Physiologic effect
Local Anesthesia
Chemical structure
Amides

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Lidocaine?

13 organisations hold an active US FDA Type II Drug Master File or a CEP for Lidocaine: Apex Healthcare Limited (India), CAMBREX KARLSKOGA AB (Sweden), DELTA SYNTHETIC CO LTD (Taiwan), HARMAN FINOCHEM LTD (India), MOEHS IBERICA SL (Spain), SWATI SPENTOSE PRIVATE LTD (India), HENAN DONGTAI PHARM CO LTD (China) and MAHENDRA CHEMICALS (India), and 5 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Lidocaine Drug Master Files are active?

Apex Healthcare Limited (DMF 34109), CAMBREX KARLSKOGA AB (DMF 19532), DELTA SYNTHETIC CO LTD (DMF 11339), HARMAN FINOCHEM LTD (DMF 27180), MOEHS IBERICA SL (DMF 13235), SWATI SPENTOSE PRIVATE LTD (DMF 25830), HENAN DONGTAI PHARM CO LTD (DMF 44454) and MAHENDRA CHEMICALS (DMF 24050) and 3 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Lidocaine records mean?

7 organisations have only inactive Type II DMFs for Lidocaine. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Lidocaine have a European Certificate of Suitability?

Yes. 8 organisations hold a valid CEP for Lidocaine on the EDQM register, including APEX HEALTHCARE LIMITED Ankleshwar (IN), SHANDONG CHENGHUI SHUANGDA PHARMACEUTICAL CO., LTD. Dezhou City (CN), HARMAN FINOCHEM LIMITED Mumbai (IN), SWATI SPENTOSE PRIVATE LIMITED Mumbai (IN), Moehs Iberica S.L. Rubi (ES) and SOCIETÀ ITALIANA MEDICINALI SCANDICCI S.I.M.S. S.R.L Reggello (IT) and 2 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Lidocaine?

Yes. The latest patent listed for an approved US product containing Lidocaine expires 10 May 2031, across 102 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Lidocaine supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Lidocaine?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.